FCF Life Sciences
Venture Capital Monitor
-
Europe

The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.

FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous slide
Next slide

As of the end of April 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 2,446m
  • Top 5 Deals exceed EUR 90m each, largest transaction amounted to EUR 138m in Distalmotion (Switzerland)
  • Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by Novo Holdings (Denmark) and Gilde Healthcare Partners (Netherlands)
  • Biotech received 53% of the total investment volume (+3% compare to the previous month)
  • Oncology dominates as the top indication in Biotechnology
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous slide
Next slide

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS